Skip to content

Klaus Langohr

6 papers in the library · 645 citations · publishing 2006-2012

Papers

Sort Most recent Most cited

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

PLoS One October 24, 2012 Ricardo Pardo‐lozano, M. Farré, Samanta Yubero‐lahoz et al. 67 citations

The synthetic psychostimulant MDMA (±3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have satisfactorily evaluated the factors contributing to...

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Current Pharmaceutical Design September 12, 2012 Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al. 288 citations

RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...

Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study

Journal of Psychopharmacology January 21, 2008 Susana de Sola Llopis, Mónica Miguélez-Pan, Jordi Peña‐Casanova et al. 58 citations

There is important preclinical evidence of long lasting neurotoxic and selective effects of ecstasy MDMA on serotonin systems in non-human primates. In humans long-term recreational use of ecstasy has been mainly associated with learning and memory impairments. The aim of the present study was to investigate the neuropsychological profile associated with ecstasy use within recreational polydrug...

Relative Abuse Liability of γ-Hydroxybutyric Acid, Flunitrazepam, and Ethanol in Club Drug Users

Journal of Clinical Psychopharmacology December 1, 2007 Sergio Abanades, Magı́ Farré, Diego Barral et al. 69 citations

OBJECTIVES: Despite the increasing concern about gamma-hydroxybutyric acid (GHB) toxicity, there are few studies examining the clinical pharmacology of GHB and its abuse potential. To evaluate GHB-induced subjective and physiological effects, its relative abuse liability and its impact on psychomotor performance in club drug users. MATERIALS AND METHODS: Twelve healthy male recreational users...

Combined immunomodulating properties of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis in humans

Addiction May 22, 2007 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 39 citations

ABSTRACT Aims Cell‐mediated immune function and the occurrence of mild infectious diseases was investigated. Participants Polydrug consumers of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis ( n = 37) compared to cannabis users only ( n = 23) and control group ( n = 34). Design A longitudinal prospective study with three cross‐sectional evaluations at time 0 and at 6 months and 1 year...

γ‐Hydroxybutyrate (GHB) in Humans

Annals of the New York Academy of Sciences August 1, 2006 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 124 citations

Despite gamma-hydroxybutyrate (GHB) therapeutic uses and the increasing concern about its toxicity, few studies have addressed GHB dose-related effects under controlled administration and their relationship with its pharmacokinetics. The study design was double-blind, randomized, crossover, and controlled. As a pilot pharmacology phase I study, increasing doses of GHB were given. Single oral...